ArticleOncoimmunology
Immunological and classical subtypes of oral premalignant lesions.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Transcriptomic landscape of oral potentially malignant disorders: a meta-analysis approach.Human cell · 2026Pooled it
- Immune suppression, HLA-risk and potential future immune based targets of oral leukoplakia progression.Frontiers in dental medicine · 2026Review
- Adaptive immune responses associated with the progression of premalignant lesions to colorectal cancer.Scientific reports · 2025Article
- A novel AI-based score for assessing the prognostic value of intra-epithelial lymphocytes in oral epithelial dysplasia.British journal of cancer · 2025Article
- Identify characteristics of Vietnamese oral squamous cell carcinoma patients by machine learning on transcriptome and clinical-histopathological analysis.Journal of dental sciences · 2024Article
- Oral Pre-malignancy: An Update on Novel Therapeutic Approaches.Current oncology reports · 2024Review
- Evaluation of the Role of C-reactive Protein as a Prognostic Indicator in Oral Pre-malignant and Malignant Lesions.Cureus · 2024Article
- Molecular characterization of the evolution of premalignant lesions in the upper aerodigestive tract.Frontiers in oncology · 2024Article
- Precancerous Lesions of the Head and Neck Region and Their Stromal Aberrations: Piecemeal Data.Cancers · 2023Review
- Bioinformatics analysis of miRNA and its associated genes to identify potential biomarkers of oral submucous fibrosis and oral malignancy.Cancer reports (Hoboken, N.J.) · 2023Article
- Understanding precancerous lesions of the oral cavityThe Journal of pathology · 2022Article
- T-Cell Infiltration and Immune Checkpoint Expression Increase in Oral Cavity Premalignant and Malignant Disorders.Biomedicines · 2022Article
- Identification of a Gene-Expression-Based Surrogate of Genomic Instability during Oral Carcinogenesis.Cancers · 2022Article
- Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.Frontiers in oral health · 2022Review
- Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy.Frontiers in immunology · 2022Review
- Transcriptional analysis highlights three distinct immune profiles of high-risk oral epithelial dysplasia.Frontiers in immunology · 2022Article
- Contribution of Genomics to the Surgical Management and Study of Oral Cancer.Annals of surgical oncology · 2021Review
- Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies.Cancers · 2021Review
- Resection Margins in Head and Neck Cancer Surgery: An Update of Residual Disease and Field Cancerization.Cancers · 2021Review
- Immune evasion in HPVProceedings of the National Academy of Sciences of the United States of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC) is a major cause of cancer-associated morbidity and mortality and may develop from oral premalignant lesions (OPL). An improved molecular classification of OPL may help refining prevention strategies. We identified two main OPL gene-expression subtypes, named immunological and classical, in 86 OPL (discovery dataset). A gene expression-based score was then developed to classify OPL samples from three independent datasets, including 17 (GSE30784),13 (GSE10174) and 15 (GSE85195) OPLs, into either one of the two gene-expression subtypes. Using the single sample gene set enrichment analysis, enrichment scores for immune-related pathways were different between the two OPL subtypes. In OPL from the discovery set, loss of heterozygosities (LOH) at 3p14, 17p13, TP53, 9p21 and 8p22 and miRNA gene expression profiles were analyzed. Deconvolution of the immune infiltrate was performed using the Microenvironment Cell Populations-counter tool. A multivariate analysis revealed that decreased miRNA-142-5p expression (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.